STAT+: The latest updates on cancer research from the weekend

Want to stay up to date on the science and politics driving biotechnology today? Sign up to receive our biotech newsletter in your inbox.

Hello, it’s Meghana. A lot happened last weekend! We have news for you from the annual meeting of the American Association for Cancer Research, as well as the annual meeting of the American College of Cardiology. Interesting things.

WHO scientists question the Grail endpoint for multi-cancer testing

A team of WHO scientists are questioning Grail’s approach to evaluating the efficacy of its multi-cancer early detection test, Galleri. The company is in the middle of two very large studies to determine how useful the test is: it is being evaluated in a 140,000-person trial in the UK’s National Health Service and in a 50,000-patient study of Medicare participants in the US. to investigate how many patients who undergo the test are diagnosed with late-stage cancer, compared to a control group that does not take the test.

Continue to STAT+ to read the full story…